Healx Appoints Christopher Moertel, M.D., as Global Head of Clinical Development

May 06, 2025 05:41 PM AEST | By EIN Presswire

Google News:

Healx Appoints Christopher Moertel, M.D., as Global Head of Clinical Development — Image source: EIN Presswire

Recent News

ACCELQ Autopilot Named “AI-based Engineering Solution of the Year” in...

Canva Breaks Ground as First Design Connector for OpenAI's ChatGPT

Hydrostor Brings on Former Shell Executive, Glenn Wright, as New Membe...

Volt Lithium Announces Approval of Name Change to LibertyStream Infras...

CAMBRIDGE, UNITED KINGDOM, May 6, 2025 /EINPresswire.com/ -- Healx, a leading AI-driven drug discovery company focused on rare diseases, today announced the appointment of Christopher Moertel, M.D., as Global Head of Clinical Development.

Dr. Moertel is a highly respected expert in neurofibromatosis (NF) and pediatric oncology. He previously served as the Kenneth and Betty Jayne Dahlberg Professor of Pediatrics at the University of Minnesota School of Medicine, where he directed the Pediatric Neuro-Oncology and Neurofibromatosis Programs. Dr. Moertel was the lead investigator in the ReNeu clinical trial of mirdametinib, which later received FDA approval as Gomekli for NF1-associated plexiform neurofibromas (NF1-PN).

At Healx, Dr. Moertel will oversee the company's clinical strategy, with a focus on advancing its pipeline of therapies for rare diseases and successfully delivering clinical trial programs.

“We are thrilled to welcome Dr. Moertel to Healx,” said Tim Guilliams, Ph.D., CEO and Co-Founder of Healx. “His leadership and rare disease expertise will be instrumental as we move our therapies closer to patients in need.”

Dr. Moertel added, “I am excited to join Healx’s mission to transform rare disease treatment through innovative science and patient-centered development. I look forward to working with the team to drive forward clinical programs that can have a meaningful impact.”

Dr. Moertel’s appointment reinforces Healx’s commitment to expanding its clinical operations and accelerating the development of new therapies for underserved patient communities.

About Healx
Healx is an AI-powered, patient-inspired tech company focused on accelerating the discovery and development of treatments for rare diseases. Founded in Cambridge, UK, Healx’s proprietary technology and pharmacology expertise aim to deliver innovative therapies to patients faster and more efficiently.
www.healx.io

Myrta Barell
Healx
+41 792344650
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.